QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … information or to RSVP, please contact Sariette Witte at ir@proqr.com . OTS The abstract titled: 'QR-010 penetrates …
… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, April 25, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … molecule that will move into clinical development using ProQR’s RNA approach. ARVO The p.Cys998X mutation which is a …
… ProQR to Present Interim Phase 1/2 Results for QR-110 in … and will be made available in the “Investors” section of ProQR’s website ( www.proqr.com ) under “Events and Presentations”. About …
QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course
QR-110 was well-tolerated with no serious adverse events